GET DAILY SIGNALSCalciMedica (CALC): Targeting CRAC Channels for Inflammatory Conditions
Key Takeaways
- CALC is the ticker for CalciMedica, Inc., a clinical-stage biopharmaceutical company headquartered in La Jolla, California.
- The company develops drugs that inhibit calcium release-activated calcium (CRAC) channels, a mechanism intended to treat serious inflammatory, immunologic, and cardiopulmonary diseases.
- Its lead candidate, Auxora (zegocractin), is being studied for acute pancreatitis and pulmonary arterial hypertension; a second candidate, CM5480, is an oral therapy in earlier development.
- As a clinical-stage company, CalciMedica has no approved products and no product revenue, funding its operations primarily through equity and debt financings.
- The company began trading on the Nasdaq under its current structure in 2023 following a merger with Graybug Vision.
Company Background
CalciMedica, Inc. (CALC) is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious diseases driven by inflammation and cellular injury. The company overview centers on a proprietary technology platform that targets calcium release-activated calcium (CRAC) channels — structures involved in the immune response and in tissue damage during acute and chronic illness. Because CalciMedica is still in the development phase, it generates no product revenue and its financial profile is defined by research-and-development spending and capital-raising rather than sales. Investors follow the stock primarily for the clinical and regulatory progress of its pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Founding and Business Model
CalciMedica was founded in 2007 by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research and is headquartered in La Jolla, California. The company became publicly listed under its current name and ticker in March 2023, when the private CalciMedica combined with the publicly traded Graybug Vision, which then adopted the CalciMedica name.
The company's business model is built around discovering and advancing a class of drugs known as CRAC channel inhibitors. CRAC channels regulate the entry of calcium into cells and are involved in immune activation and in the tissue injury seen in inflammatory diseases. By inhibiting these channels, CalciMedica aims to modulate the immune response while protecting organs such as the pancreas, lungs, and kidneys from damage.
CalciMedica's pipeline contains two main product candidates:
- Auxora (zegocractin), the lead candidate, formulated for intravenous (IV) administration. Auxora has been evaluated in multiple completed clinical trials, including studies in acute pancreatitis and in patients with COVID-19 pneumonia, and is now being advanced toward a pivotal program in acute pancreatitis as well as a planned proof-of-concept study in pulmonary arterial hypertension.
- CM5480, a proprietary oral CRAC channel inhibitor designed for chronic dosing, in development for pulmonary hypertension.
Because it has no approved therapies, CalciMedica's primary "revenue sources" are effectively nonexistent from a commercial standpoint; the company instead relies on financing activities such as equity offerings, private placements, and debt instruments to fund its research and development. Its competitive positioning is that of an early-stage developer pursuing a differentiated mechanism of action in diseases — most notably acute pancreatitis — for which no therapies are currently approved by the U.S. Food and Drug Administration (FDA).
Why the Stock Draws Interest
CalciMedica attracts attention largely because of the unmet medical need in its target indications. Acute pancreatitis, for example, is a serious inflammatory disease with no FDA-approved treatment and roughly 300,000 hospitalizations annually in the United States alone. A drug able to reduce severe complications such as respiratory failure or organ failure in these patients could address a significant market opportunity.
The company's CRAC channel platform also represents a potential new class of anti-inflammatory medicines, which supports long-term growth drivers tied to pipeline expansion rather than near-term sales. Investors and analysts monitor CalciMedica for clinical data readouts, regulatory feedback from the FDA, and the progress of its oral candidate CM5480, which could broaden the company's addressable patient populations if it advances successfully. From what I see, this mechanism stands out in a crowded biotech space.
Key Risks to Consider
Investing in CalciMedica carries substantial risk typical of early-stage biotechnology companies. The company has no approved products, no commercial revenue, and a history of operating losses, and it depends on raising additional capital to continue its research. Its future value hinges on clinical trial outcomes, which are inherently uncertain; earlier-stage results may not predict success in larger or later trials, and trials can be paused, redesigned, or discontinued for safety or efficacy reasons.
Regulatory risk is also significant, as candidate therapies must secure FDA approval before they can be sold. Competition is another factor: although acute pancreatitis currently lacks an approved therapy, larger pharmaceutical and biotechnology companies could pursue similar targets. Finally, CalciMedica's small market capitalization and limited cash position make it sensitive to financing conditions and to dilutive equity raises, which can affect existing shareholders.
Using AI Tools for Biotech Research
In my own workflow, Tickeron’s AI Screener has become a useful resource for quickly comparing clinical-stage names like CALC against peers based on technical signals, fundamentals, and volatility filters. It allows me to apply custom criteria across thousands of equities without spending hours on manual screening, which helps surface ideas that align with a given risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CALC's RSI Indicator climbs out of oversold territory
The RSI Indicator for CALC moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 29 of the 33 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 66 cases where CALC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +16.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CALC advanced for three days, in 185 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CALC as a result. In 67 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
CALC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CALC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.684) is normal, around the industry mean (3.498). P/E Ratio (-0.199) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CALC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement